Cerebrospinal fluid biomarkers in clinical subtypes of early-onset alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 37, Issue 5-6, 2014, Pages 307-314

  Teng, Edmond ^a,b   Yamasaki, Tritia R ^a   Tran, Michelle ^a   Hsiao, Julia J ^a,b   Sultzer, David L ^a,b   Mendez, Mario F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Amyloid; Biological markers; Cerebrospinal fluid; Early onset Alzheimer's disease; Logopenic progressive aphasia; Posterior cortical atrophy; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PHOSPHO TAU PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; AMNESIA; APHASIA; ARTICLE; BRAIN CORTEX ATROPHY; CEREBROSPINAL FLUID ANALYSIS; COMPARATIVE STUDY; FEMALE; HUMAN; LOGOPENIC PROGRESSIVE APHASIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; CASE CONTROL STUDY; CEREBROSPINAL FLUID; CLASSIFICATION; COHORT ANALYSIS; MIDDLE AGED; PHOSPHORYLATION; RETROSPECTIVE STUDY; ADULT; CLINICAL FEATURE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RETROSPECTIVE STUDIES; TAU PROTEINS;

EID: 84891720363     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000355555     Document Type: Article

References (41)

1. Mendez MF, Lee AS, Joshi A, Shapira JS: Nonamnestic presentations of early-onset Alzheimer's disease. Am J Alzheimers Dis Other Demen 2012; 27: 413-420
2. Mendez MF: Early-onset Alzheimer's disease: Nonamnestic subtypes and type 2 AD. Arch Med Res 2012; 43: 677-685
3. Stopford CL, Snowden JS, Thompson JC, Neary D: Variability in cognitive presentation of Alzheimer's disease. Cortex 2008; 44: 185-195. (Pubitemid 351729233)
4. Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, Hodges JR: Focal cortical presentations of Alzheimer's disease. Brain 2007; 130: 2636-2645. (Pubitemid 47511719)
5. Davidson Y, Gibbons L, Pritchard A, Hardicre J, Wren J, Stopford C, Julien C, Thompson J, Payton A, Pickering- Brown SM, Pendleton N, Horan MA, Burns A, Purandare N, Lendon CL, Neary D, Snowden JS, Mann DM: Apolipoprotein E epsilon4 allele frequency and age at onset of Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 23: 60-66. (Pubitemid 46005793)
6. van der Flier WM, Pijnenburg YA, Fox NC, Scheltens P: Early-onset versus late-onset Alzheimer's disease: The case of the missing ApoE epsilon4 allele. Lancet Neurol 2011; 10: 280-288
7. Koedam EL, Pijnenburg YA, Deeg DJ, Baak MM, van der Vlies AE, Scheltens P, van der Flier WM: Early-onset dementia is associated with higher mortality. Dement Geriatr Cogn Disord 2008; 26: 147-152
8. Schott JM, Ridha BH, Crutch SJ, Healy DG, Uphill JB, Warrington EK, Rossor MN, Fox NC: Apolipoprotein E genotype modifies the phenotype of Alzheimer disease. Arch Neurol 2006; 63: 155-156. (Pubitemid 43063881)
9. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW: Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: A retrospective study. Lancet Neurol 2011; 10: 785-796
10. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH: The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269
11. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M: Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006-1014
12. Mendez MF, Ghajarania M, Perryman KM: Posterior cortical atrophy: Clinical characteristics and differences compared to Alzheimer's disease. Dement Geriatr Cogn Disord 2002; 14: 33-40
13. Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook R, Caselli RJ, Knopman DS, Petersen RC: Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004; 63: 1168-1174. (Pubitemid 39350012)
14. Hunt DC: Young-onset dementia: A review of the literature and what it means for clinicians. J Psychosoc Nurs Ment Health Serv 2011; 49: 28-33
15. Beaufils E, Dufour-Rainfray D, Hommet C, Brault F, Cottier JP, Ribeiro MJ, Mondon K, Guilloteau D: Confirmation of the amyloidogenic process in posterior cortical atrophy: Value of the abeta42/abeta40 ratio. J Alzheimers Dis 2013; 33: 775-780
16. Seguin J, Formaglio M, Perret-Liaudet A, Quadrio I, Tholance Y, Rouaud O, Thomas-Anterion C, Croisile B, Mollion H, Moreaud O, Salzmann M, Dorey A, Bataillard M, Coste MH, Vighetto A, Krolak-Salmon P: CSF biomarkers in posterior cortical atrophy. Neurology 2011; 76: 1782-1788
17. Formaglio M, Costes N, Seguin J, Tholance Y, Le Bars D, Roullet-Solignac I, Mercier B, Krolak-Salmon P, Vighetto A: In vivo demonstration of amyloid burden in posterior cortical atrophy: A case series with PET and CSF findings. J Neurol 2011; 258: 1841-1851
18. de Souza LC, Corlier F, Habert MO, Uspenskaya O, Maroy R, Lamari F, Chupin M, Lehericy S, Colliot O, Hahn- Barma V, Samri D, Dubois B, Bottlaender M, Sarazin M: Similar amyloid-beta burden in posterior cortical atrophy and Alzheimer's disease. Brain 2011; 134: 2036-2043
19. Baumann TP, Duyar H, Sollberger M, Kuhle J, Regeniter A, Gomez-Mancilla B, Schmidtke K, Monsch AU: CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy. Dement Geriatr Cogn Disord 2010; 29: 530-533
20. de Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, De Paz R, Dubois B, Sarazin M: Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J Neurol Neurosurg Psychiatry 2011; 82: 240-246
21. Hu WT, McMillan C, Libon D, Leight S, Forman M, Lee VM, Trojanowski JQ, Grossman M: Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia. Neurology 2010; 75: 595-602
22. Rohrer JD, Rossor MN, Warren JD: Syndromes of nonfluent primary progressive aphasia: A clinical and neurolinguistic analysis. Neurology 2010; 75: 603-610
23. Kas A, Uspenskaya O, Lamari F, de Souza LC, Habert MO, Dubois B, Teichmann M, Sarazin M: Distinct brain perfusion pattern associated with CSF biomarkers profile in primary progressive aphasia. J Neurol Neurosurg Psychiatry 2012; 83: 695-698
24. Gil-Navarro S, Llado A, Rami L, Castellvi M, Bosch B, Bargallo N, Lomena F, Rene R, Montagut N, Antonell A, Molinuevo JL, Sanchez-Valle R: Neuroimaging and biochemical markers in the three variants of primary progressive aphasia. Dement Geriatr Cogn Disord 2013; 35: 106-117
25. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid beta-Amyloid(1-42) in Alzheimer disease: Differences between early- And late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999; 56: 673-680
26. Iqbal K, Flory M, Khatoon S, Soininen H, Pirttila T, Lehtovirta M, Alafuzoff I, Blennow K, Andreasen N, Vanmechelen E, Grundke-Iqbal I: Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 2005; 58: 748-757. (Pubitemid 41552550)
27. Gronning H, Rahmani A, Gyllenborg J, Dessau RB, Hogh P: Does Alzheimer's disease with early onset progress faster than with late onset? A case-control study of clinical progression and cerebrospinal fluid biomarkers. Dement Geriatr Cogn Disord 2012; 33: 111-117
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944
29. Tsai PH, Teng E, Liu C, Mendez MF: Posterior cortical atrophy: Evidence for discrete syndromes of early-onset Alzheimer's disease. Am J Alzheimers Dis Other Demen 2011; 26: 413-418
30. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
31. Koric L, Felician O, Guedj E, Hubert AM, Mancini J, Boucraut J, Ceccaldi M: Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease? Alzheimer Dis Assoc Disord 2010; 24: 278-283
32. Tapiola T, Overmyer M, Lehtovirta M, Helisalmi S, Ramberg J, Alafuzoff I, Riekkinen P Sr, Soininen H: The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 1997; 8: 3961-3963. (Pubitemid 28027217)
33. Buerger K, Alafuzoff I, Ewers M, Pirttila T, Zinkowski R, Hampel H: No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2007; 130:e82
34. Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, Kornhuber J, Wiltfang J: Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: Original data and review of the literature. J Mol Neurosci 2004; 23: 115-122. (Pubitemid 41359194)
35. Mesulam M, Wicklund A, Johnson N, Rogalski E, Leger GC, Rademaker A, Weintraub S, Bigio EH: Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008; 63: 709-719. (Pubitemid 351945530)
36. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ: Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 2010; 45: 30-40
37. Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM: CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 2009; 73: 1353-1358
38. Renner JA, Burns JM, Hou CE, McKeel DW Jr, Storandt M, Morris JC: Progressive posterior cortical dysfunction: A clinicopathologic series. Neurology 2004; 63: 1175-1180
39. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413
40. Lehmann M, Ghosh PM, Madison C, Laforce R Jr, Corbetta-Rastelli C, Weiner MW, Greicius MD, Seeley WW, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD: Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain 2013; 136: 844-858
41. Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Hakan W, Decraemer H, Nagga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O: Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012; 69: 1445-1452.